Payment overview · 2025
General Payments
$561.55
30 reported records · 18 companies
Healthcare provider profile · identity verified
Claes U Svendsen, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREENEVILLE, TN · NPI 1801836572
Verified facts
What the public records show
CMS Open Payments records show Claes U Svendsen, MD received $561.55 in general payments during 2025 across 30 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $130.50 | 23.2% | 6 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $59.84 | 10.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.92 | 8.9% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $45.20 | 8.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.70 | 7.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.11 | 7.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.01 | 3.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.65 | 3.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.44 | 3.1% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $17.19 | 3.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.47 | 2.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.68 | 2.8% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.34 | 2.5% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $14.22 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.17 | 2.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.77 | 2.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.69 | 2.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.65 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $561.55 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $130.50 | 6 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $59.84 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $45.20 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $42.11 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.11 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 167 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 94 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
94 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
103 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
167 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 635 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 479 | 141 |
| Atorvastatin Calcium | Atorvastatin Calcium | 473 | 137 |
| Gabapentin | Gabapentin | 464 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 463 | 135 |
| Furosemide | Furosemide | 439 | 147 |
| Omeprazole | Omeprazole | 435 | 118 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 396 | 133 |
| Lisinopril | Lisinopril | 383 | 110 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 379 | 53 |
| Montelukast Sodium | Montelukast Sodium | 378 | 106 |
| Potassium Chloride | Potassium Chloride | 300 | 96 |
| Famotidine | Famotidine | 297 | 101 |
| Hydrochlorothiazide | Hydrochlorothiazide | 288 | 92 |
| Losartan Potassium | Losartan Potassium | 285 | 84 |
| Trazodone Hcl | Trazodone Hcl | 280 | 75 |
| Metformin Hcl | Metformin Hcl | 274 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 253 | 77 |
| Sertraline Hcl | Sertraline Hcl | 252 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 245 | 69 |
| Tizanidine Hcl | Tizanidine Hcl | 243 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 230 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 225 | 64 |
| Prednisone | Prednisone | 223 | 149 |
| Carvedilol | Carvedilol | 173 | 49 |
| Allopurinol | Allopurinol | 169 | 43 |
| Eliquis | Apixaban | 167 | 34 |
| Tramadol Hcl | Tramadol Hcl | 167 | 42 |
| Baclofen | Baclofen | 152 | 39 |
| Meloxicam | Meloxicam | 152 | 48 |
| Simvastatin | Simvastatin | 145 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 48 |
| Alprazolam | Alprazolam | 137 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 124 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 123 | 34 |
| Pregabalin | Pregabalin | 109 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 107 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 31 |
| Trulicity | Dulaglutide | 103 | 20 |
| Metformin Hcl Er | Metformin Hcl | 100 | 30 |
| Buspirone Hcl | Buspirone Hcl | 99 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 25 |
| Atenolol | Atenolol | 94 | 29 |
| Mounjaro | Tirzepatide | 94 | 12 |
| Ozempic | Semaglutide | 92 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 18 |
| Finasteride | Finasteride | 85 | 25 |
| Xarelto | Rivaroxaban | 83 | 17 |
| Glimepiride | Glimepiride | 78 | 21 |
| Colchicine | Colchicine | 75 | 23 |
| Lactulose | Lactulose | 73 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 49 |
| Ibuprofen | Ibuprofen | 71 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 69 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 17 |
| Alendronate Sodium | Alendronate Sodium | 65 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 59 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 20 |
| Diazepam | Diazepam | 62 | 16 |
| Liothyronine Sodium | Liothyronine Sodium | 60 | 16 |
| Azithromycin | Azithromycin | 58 | 54 |
| Lovastatin | Lovastatin | 58 | 15 |
| Nystatin | Nystatin | 58 | 35 |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 16 |
| Warfarin Sodium | Warfarin Sodium | 55 | 11 |
| Benazepril Hcl | Benazepril Hcl | 54 | 16 |
| Jardiance | Empagliflozin | 54 | 14 |
| Meclizine Hcl | Meclizine Hcl | 54 | 27 |
| Nitroglycerin | Nitroglycerin | 54 | 37 |
| Januvia | Sitagliptin Phosphate | 53 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 13 |
| Risperidone | Risperidone | 51 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | 14 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Estradiol | Estradiol | 45 | 12 |
| Spironolactone | Spironolactone | 45 | 13 |
| Azelastine Hcl | Azelastine Hcl | 43 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 37 |
| Donepezil Hcl | Donepezil Hcl | 42 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 42 | 17 |
| Novolog Flexpen | Insulin Aspart | 42 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 11 |
| Celecoxib | Celecoxib | 37 | 15 |
| Chlorthalidone | Chlorthalidone | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Clonidine | Clonidine | 36 | suppressed |
| Valsartan | Valsartan | 36 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 11 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 18 |
| Ketoconazole | Ketoconazole | 33 | 15 |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | 11 |
| Telmisartan | Telmisartan | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 24 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $561.55 · 30 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AREXVY, Auvelity, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENFLONSIA, GARDASIL 9, GEMTESA, GIMOTI, GVOKE HYPOPEN, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VRAYLAR, Wegovy, XYOSTED, YUPELRI, Yorvipath, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error